Wet Age-Related Macular Degeneration

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, David S. Boyer, MD, discusses the progress of two phase 3 clinical trials for OPT-302 in combination with either ranibizumab or aflibercept.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Terry Dagnon, chief operations officer for Outlook Therapeutics, discusses the latest update on ONS-5010 for the treatment of wet AMD.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Nancy Lurker, president and CEO of EyePoint Pharmaceuticals, discusses the latest update on EYP-1901.

DENVER — A higher 8 mg dose of aflibercept for the treatment of wet AMD resulted in patients having a two- or three-letter improvement in visual acuity vs. the traditional 2 mg dose, David Brown, MD, said here at ARVO.

DENVER — High-dose aflibercept maintained visual acuity in patients with neovascular age-related macular degeneration at 48 months, according to a study presented at the Association for Research in Vision and Ophthalmology meeting.

DENVER — In this Healio Video Perspective from the ARVO meeting, Jason S. Slakter, MD, discusses his poster on phase 2b study results of OPT-302 (Opthea) in combination with ranibizumab for wet age-related macular degeneration.

WASHINGTON — Age-related macular degeneration has a significant impact on vision across the population, according to a speaker here.

The European Commission has granted approval to Beovu for the treatment of visual impairment caused by diabetic macular edema, according to a press release from Novartis.

In this episode I share my top 5 predictions in ophthalmology for 2022, including my thoughts on the future of COVID-19 and ocular gene therapy.

In this episode, hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news in eye care, then speak with Eric Rosenberg, DO, about the current state and future of digital ophthalmology.